Key facts
- It has raised $900K; the latest was Later Stage VC ($900K) in Mar 2026.
- Notable investors include University of Toronto, University of California, Healthspan Capital, Los Angeles.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Metanoia
- ·The full record, as it builds
Funding rounds
No funding rounds for Metanoia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Metanoia
Operator of a biotechnology research company intended for functional tissue regeneration. The company offers a proprietary platform based on modifying an evolutionarily conserved pathway for physiologically induced tissue regeneration, with diversified therapeutic applications in diabetes, diabetic retinopathy, pancreatic cancer, Alzheimer's Disease, and heart failure, enabling healthcare providers to gain access to technology and implement it in services.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2020
- Employees
- 5
- Website
- metanoia.bio/
- Ownership
- Privately Held (backing)
Metanoia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Metanoia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Metanoia in its N-PORT filings yet. We sweep new filings monthly.